Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

The projects are part of a collaboration with technology transfer company Yissum, a business partner of renowned firms like Boston Scientific (NYSE: BSX), ICL (NYSE: ICL), Intel (NASDAQ: INTC), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK) and Novartis (NYSE: NVS).
The first project is intended to research and discover innovative synthetic molecules based on known psychedelic chemicals.

The second venture aimed to synthesize and evaluate the potential therapeutic effect of several chemical psychedelic analogs.

Yissum — a bridge between novel academic research and worldwide entrepreneurs, investors and industries — has registered 11,000 patents, licensed 1,140 technologies and spun out more than 200 companies globally since it was founded in 1964.

Both projects delivered several promising drug candidates. The partners are now advancing the candidates into fresh patent applications.

Clearmind CEO Adi Zuloff-Shani praised the results as “proof of the fruitful collaboration between Clearmind and leading academic institutions.” 

These kinds of projects align with the company’s “overarching mission” of developing its intellectual product portfolio for next-generation novel psychedelic drug candidates and serving patients with unmet medical needs through a “state-of-the-art drug discovery approach in medicinal chemistry and pharmacology,” Zuloff-Shani added.

Photo: Benzinga edit with photo by Pexels.